Title: Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Authors: Devonshire, Virginia
Havrdova, Eva
Radue, Ernst Wilhelm
O'Connor, Paul
Zhang-Auberson, Lixin
Agoropoulou, Catherine
Häring, Dieter Adrian
Francis, Gordon
Kappos, Ludwig
FREEDOMS study group
Contributors: Dubois, Bénédicte
Issue Date: May-2012
Publisher: Lancet Pub. Group
Series Title: The Lancet Neurology vol:11 issue:5 pages:420-8
Article number: 10.1016/S1474-4422(12)70056-X
Abstract: Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics.
ISSN: 1474-4422
Publication status: published
KU Leuven publication type: DI
Appears in Collections:Laboratory for Neuroimmunology

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science